Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon

Joseph B.J. Ward, Natalia K. Lajczak, Orlaith B Kelly, Aoife M. O'Dwyer, Ashwini K Giddam, Joan N Ní Gabhainn, Placido Franco, Murtaza M Tambuwala, Caroline A Jefferies, Simon Keely, Aldo Roda, Stephen Joseph Keely

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Inflammatory bowel diseases (IBD) are a group of common and debilitating chronic intestinal disorders for which currently-available therapies are often unsatisfactory. The naturally-occurring secondary bile acid, ursodeoxycholic acid (UDCA), has well-established anti-inflammatory and cytoprotective actions and may therefore be effective in treating IBD. Here, we aimed to investigate regulation of colonic inflammatory responses by UDCA and to determine the potential impact of bacterial metabolism on its therapeutic actions. The anti-inflammatory efficacy of UDCA, a non-metabolisable analogue, 6-methyl-UDCA (6-MUDCA), and its primary colonic metabolite, lithocholic acid (LCA), were assessed in the murine DSS model of mucosal injury. The effects of bile acids on cytokine release (TNF-α, IL-6, Il-1β, IFN-γ) from cultured colonic epithelial cells and mouse colonic tissue in vivo were investigated. Luminal bile acids were measured by GC-MS. UDCA attenuated release of proinflammatory cytokines from colonic epithelial cells in vitro and was protective against the development of colonic inflammation in vivo. In contrast, although 6-MUDCA mimicked the effects of UDCA on epithelial cytokine release in vitro, it was ineffective in preventing inflammation in the DSS model. In UDCA-treated mice, LCA became the most common colonic bile acid. Finally, LCA treatment more potently inhibited epithelial cytokine release and protected against DSS-induced mucosal inflammation than did UDCA. These studies identify a new role for the primary metabolite of UDCA, LCA, in preventing colonic inflammation and suggest that microbial metabolism of UDCA is necessary for the full expression of its protective actions.
LanguageEnglish
PagesG550-G558
JournalAJP - Gastrointestinal and Liver Physiology
Volume312
Issue number6
Early online date30 Mar 2017
DOIs
Publication statusE-pub ahead of print - 30 Mar 2017

Fingerprint

Lithocholic Acid
Ursodeoxycholic Acid
Colon
Anti-Inflammatory Agents
Bile Acids and Salts
Cytokines
Inflammation
Inflammatory Bowel Diseases
Epithelial Cells
Interleukin-6
Tumor Necrosis Factor-alpha

Keywords

  • inflammatory bowel disease
  • bile acid
  • Epithelium
  • Cytokine
  • barrier function

Cite this

Ward, J. B. J., Lajczak, N. K., Kelly, O. B., O'Dwyer, A. M., Giddam, A. K., Ní Gabhainn, J. N., ... Keely, S. J. (2017). Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. AJP - Gastrointestinal and Liver Physiology, 312(6), G550-G558. https://doi.org/10.1152/ajpgi.00256.2016
Ward, Joseph B.J. ; Lajczak, Natalia K. ; Kelly, Orlaith B ; O'Dwyer, Aoife M. ; Giddam, Ashwini K ; Ní Gabhainn, Joan N ; Franco, Placido ; Tambuwala, Murtaza M ; Jefferies, Caroline A ; Keely, Simon ; Roda, Aldo ; Keely, Stephen Joseph. / Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. In: AJP - Gastrointestinal and Liver Physiology. 2017 ; Vol. 312, No. 6. pp. G550-G558.
@article{f1bf44ef5ffb49fcb6375f19e042fe4e,
title = "Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon",
abstract = "Inflammatory bowel diseases (IBD) are a group of common and debilitating chronic intestinal disorders for which currently-available therapies are often unsatisfactory. The naturally-occurring secondary bile acid, ursodeoxycholic acid (UDCA), has well-established anti-inflammatory and cytoprotective actions and may therefore be effective in treating IBD. Here, we aimed to investigate regulation of colonic inflammatory responses by UDCA and to determine the potential impact of bacterial metabolism on its therapeutic actions. The anti-inflammatory efficacy of UDCA, a non-metabolisable analogue, 6-methyl-UDCA (6-MUDCA), and its primary colonic metabolite, lithocholic acid (LCA), were assessed in the murine DSS model of mucosal injury. The effects of bile acids on cytokine release (TNF-α, IL-6, Il-1β, IFN-γ) from cultured colonic epithelial cells and mouse colonic tissue in vivo were investigated. Luminal bile acids were measured by GC-MS. UDCA attenuated release of proinflammatory cytokines from colonic epithelial cells in vitro and was protective against the development of colonic inflammation in vivo. In contrast, although 6-MUDCA mimicked the effects of UDCA on epithelial cytokine release in vitro, it was ineffective in preventing inflammation in the DSS model. In UDCA-treated mice, LCA became the most common colonic bile acid. Finally, LCA treatment more potently inhibited epithelial cytokine release and protected against DSS-induced mucosal inflammation than did UDCA. These studies identify a new role for the primary metabolite of UDCA, LCA, in preventing colonic inflammation and suggest that microbial metabolism of UDCA is necessary for the full expression of its protective actions.",
keywords = "inflammatory bowel disease, bile acid, Epithelium, Cytokine, barrier function",
author = "Ward, {Joseph B.J.} and Lajczak, {Natalia K.} and Kelly, {Orlaith B} and O'Dwyer, {Aoife M.} and Giddam, {Ashwini K} and {N{\'i} Gabhainn}, {Joan N} and Placido Franco and Tambuwala, {Murtaza M} and Jefferies, {Caroline A} and Simon Keely and Aldo Roda and Keely, {Stephen Joseph}",
year = "2017",
month = "3",
day = "30",
doi = "10.1152/ajpgi.00256.2016",
language = "English",
volume = "312",
pages = "G550--G558",
journal = "AJP - Gastrointestinal and Liver Physiology",
issn = "0193-1857",
publisher = "American Physiological Society",
number = "6",

}

Ward, JBJ, Lajczak, NK, Kelly, OB, O'Dwyer, AM, Giddam, AK, Ní Gabhainn, JN, Franco, P, Tambuwala, MM, Jefferies, CA, Keely, S, Roda, A & Keely, SJ 2017, 'Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon', AJP - Gastrointestinal and Liver Physiology, vol. 312, no. 6, pp. G550-G558. https://doi.org/10.1152/ajpgi.00256.2016

Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. / Ward, Joseph B.J.; Lajczak, Natalia K.; Kelly, Orlaith B; O'Dwyer, Aoife M.; Giddam, Ashwini K; Ní Gabhainn, Joan N; Franco, Placido; Tambuwala, Murtaza M; Jefferies, Caroline A; Keely, Simon; Roda, Aldo; Keely, Stephen Joseph.

In: AJP - Gastrointestinal and Liver Physiology, Vol. 312, No. 6, 30.03.2017, p. G550-G558.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon

AU - Ward, Joseph B.J.

AU - Lajczak, Natalia K.

AU - Kelly, Orlaith B

AU - O'Dwyer, Aoife M.

AU - Giddam, Ashwini K

AU - Ní Gabhainn, Joan N

AU - Franco, Placido

AU - Tambuwala, Murtaza M

AU - Jefferies, Caroline A

AU - Keely, Simon

AU - Roda, Aldo

AU - Keely, Stephen Joseph

PY - 2017/3/30

Y1 - 2017/3/30

N2 - Inflammatory bowel diseases (IBD) are a group of common and debilitating chronic intestinal disorders for which currently-available therapies are often unsatisfactory. The naturally-occurring secondary bile acid, ursodeoxycholic acid (UDCA), has well-established anti-inflammatory and cytoprotective actions and may therefore be effective in treating IBD. Here, we aimed to investigate regulation of colonic inflammatory responses by UDCA and to determine the potential impact of bacterial metabolism on its therapeutic actions. The anti-inflammatory efficacy of UDCA, a non-metabolisable analogue, 6-methyl-UDCA (6-MUDCA), and its primary colonic metabolite, lithocholic acid (LCA), were assessed in the murine DSS model of mucosal injury. The effects of bile acids on cytokine release (TNF-α, IL-6, Il-1β, IFN-γ) from cultured colonic epithelial cells and mouse colonic tissue in vivo were investigated. Luminal bile acids were measured by GC-MS. UDCA attenuated release of proinflammatory cytokines from colonic epithelial cells in vitro and was protective against the development of colonic inflammation in vivo. In contrast, although 6-MUDCA mimicked the effects of UDCA on epithelial cytokine release in vitro, it was ineffective in preventing inflammation in the DSS model. In UDCA-treated mice, LCA became the most common colonic bile acid. Finally, LCA treatment more potently inhibited epithelial cytokine release and protected against DSS-induced mucosal inflammation than did UDCA. These studies identify a new role for the primary metabolite of UDCA, LCA, in preventing colonic inflammation and suggest that microbial metabolism of UDCA is necessary for the full expression of its protective actions.

AB - Inflammatory bowel diseases (IBD) are a group of common and debilitating chronic intestinal disorders for which currently-available therapies are often unsatisfactory. The naturally-occurring secondary bile acid, ursodeoxycholic acid (UDCA), has well-established anti-inflammatory and cytoprotective actions and may therefore be effective in treating IBD. Here, we aimed to investigate regulation of colonic inflammatory responses by UDCA and to determine the potential impact of bacterial metabolism on its therapeutic actions. The anti-inflammatory efficacy of UDCA, a non-metabolisable analogue, 6-methyl-UDCA (6-MUDCA), and its primary colonic metabolite, lithocholic acid (LCA), were assessed in the murine DSS model of mucosal injury. The effects of bile acids on cytokine release (TNF-α, IL-6, Il-1β, IFN-γ) from cultured colonic epithelial cells and mouse colonic tissue in vivo were investigated. Luminal bile acids were measured by GC-MS. UDCA attenuated release of proinflammatory cytokines from colonic epithelial cells in vitro and was protective against the development of colonic inflammation in vivo. In contrast, although 6-MUDCA mimicked the effects of UDCA on epithelial cytokine release in vitro, it was ineffective in preventing inflammation in the DSS model. In UDCA-treated mice, LCA became the most common colonic bile acid. Finally, LCA treatment more potently inhibited epithelial cytokine release and protected against DSS-induced mucosal inflammation than did UDCA. These studies identify a new role for the primary metabolite of UDCA, LCA, in preventing colonic inflammation and suggest that microbial metabolism of UDCA is necessary for the full expression of its protective actions.

KW - inflammatory bowel disease

KW - bile acid

KW - Epithelium

KW - Cytokine

KW - barrier function

U2 - 10.1152/ajpgi.00256.2016

DO - 10.1152/ajpgi.00256.2016

M3 - Article

VL - 312

SP - G550-G558

JO - AJP - Gastrointestinal and Liver Physiology

T2 - AJP - Gastrointestinal and Liver Physiology

JF - AJP - Gastrointestinal and Liver Physiology

SN - 0193-1857

IS - 6

ER -